Conclusions
This case reports a patient with stage IV lung adenocarcinoma treated
with a combination of an antiangiogenic inhibitor and an immune
checkpoint inhibitor who switched from a combination of camrelizumab and
endonuclease to a combination of camrelizumab and bevacizumab with a
sustained benefit over 18 months, suggesting that combination
immunotherapy may be a treatment option for patients with KRAS mutations
in advanced non-small cell lung cancer. Second, the combination of
anti-angiogenesis inhibitors and immunotherapy may improve efficacy and
with good persistence. Despite encouraging results from studies
evaluating the safety and efficacy of this combination therapy, there is
currently no head-to-head trial evidence comparing the therapeutic
efficacy of ICIs with other therapies such as angiogenesis inhibitors.
There is also a need to advance effective immunosurveillance techniques
that are closely linked to clinical endpoints. Significant affinities
may help to identify favorable immune biomarkers that can then be
validated in larger patient cohorts.